Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280521541> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4280521541 endingPage "130" @default.
- W4280521541 startingPage "126" @default.
- W4280521541 abstract "A common standard option for the treatment of metastatic non-small cell lung cancer (NSCLC) is a combination of platinum-based chemotherapy, pemetrexed, and pembrolizumab [ [1] Gandhi L. Rodríguez-Abreu D. Gadgeel S. Esteban E. Felip E. De Angelis F. Domine M. Clingan P. Hochmair M.J. Powell S.F. Cheng S.Y. Bischoff H.G. Peled N. Grossi F. Jennens R.R. Reck M. Hui R. Garon E.B. Boyer M. Rubio-Viqueira B. Novello S. Kurata T. Gray J.E. Vida J. Wei Z. Yang J. Raftopoulos H. Pietanza M.C. Garassino M.C. KEYNOTE-189 investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018; 378 (May 31): 2078-2092 Crossref PubMed Scopus (3096) Google Scholar ]. This combination can cause acute kidney injury (AKI) by different mechanisms. Pembrolizumab, one of the immune checkpoint inhibitors (ICIs), is a humanised monoclonal IgG4 antibody directed against programmed cell death 1 which enhances T cell-mediated cancer cell destruction. The most common mechanisms of AKI caused by ICIs are acute interstitial nephritis and sometimes glomerular disorders [ [2] Shruti Gupta Frank B. Cortazar Leonardo V. Riella David E. Immune checkpoint inhibitor nephrotoxicity: Update. Leaf Kidney. 2020; 360 (January 2020) Google Scholar ]. Hereby, we report a case of Immune Checkpoint Inhibitor Associated Renally Limited Thrombotic Microangiopathy (ICI-rTMA), review the current literature and present the unique dilemma it presents." @default.
- W4280521541 created "2022-05-22" @default.
- W4280521541 creator A5056240673 @default.
- W4280521541 creator A5056908274 @default.
- W4280521541 creator A5077502366 @default.
- W4280521541 creator A5084392688 @default.
- W4280521541 creator A5085975297 @default.
- W4280521541 date "2022-07-01" @default.
- W4280521541 modified "2023-09-29" @default.
- W4280521541 title "Immune checkpoint inhibitor associated renally limited thrombotic microangiopathy – a clinical dilemma" @default.
- W4280521541 cites W2011926111 @default.
- W4280521541 cites W2111008016 @default.
- W4280521541 cites W2413514895 @default.
- W4280521541 cites W2796582438 @default.
- W4280521541 cites W2809099134 @default.
- W4280521541 cites W3038774038 @default.
- W4280521541 cites W3122220390 @default.
- W4280521541 cites W3136751629 @default.
- W4280521541 cites W3142034339 @default.
- W4280521541 cites W3185715241 @default.
- W4280521541 cites W3185949075 @default.
- W4280521541 doi "https://doi.org/10.1016/j.ejca.2022.03.031" @default.
- W4280521541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35561455" @default.
- W4280521541 hasPublicationYear "2022" @default.
- W4280521541 type Work @default.
- W4280521541 citedByCount "5" @default.
- W4280521541 countsByYear W42805215412022 @default.
- W4280521541 countsByYear W42805215412023 @default.
- W4280521541 crossrefType "journal-article" @default.
- W4280521541 hasAuthorship W4280521541A5056240673 @default.
- W4280521541 hasAuthorship W4280521541A5056908274 @default.
- W4280521541 hasAuthorship W4280521541A5077502366 @default.
- W4280521541 hasAuthorship W4280521541A5084392688 @default.
- W4280521541 hasAuthorship W4280521541A5085975297 @default.
- W4280521541 hasConcept C121608353 @default.
- W4280521541 hasConcept C126322002 @default.
- W4280521541 hasConcept C143998085 @default.
- W4280521541 hasConcept C2776256026 @default.
- W4280521541 hasConcept C2777701055 @default.
- W4280521541 hasConcept C2777878052 @default.
- W4280521541 hasConcept C2779134260 @default.
- W4280521541 hasConcept C2780030458 @default.
- W4280521541 hasConcept C2780057760 @default.
- W4280521541 hasConcept C2780472472 @default.
- W4280521541 hasConcept C502942594 @default.
- W4280521541 hasConcept C71924100 @default.
- W4280521541 hasConceptScore W4280521541C121608353 @default.
- W4280521541 hasConceptScore W4280521541C126322002 @default.
- W4280521541 hasConceptScore W4280521541C143998085 @default.
- W4280521541 hasConceptScore W4280521541C2776256026 @default.
- W4280521541 hasConceptScore W4280521541C2777701055 @default.
- W4280521541 hasConceptScore W4280521541C2777878052 @default.
- W4280521541 hasConceptScore W4280521541C2779134260 @default.
- W4280521541 hasConceptScore W4280521541C2780030458 @default.
- W4280521541 hasConceptScore W4280521541C2780057760 @default.
- W4280521541 hasConceptScore W4280521541C2780472472 @default.
- W4280521541 hasConceptScore W4280521541C502942594 @default.
- W4280521541 hasConceptScore W4280521541C71924100 @default.
- W4280521541 hasLocation W42805215411 @default.
- W4280521541 hasLocation W42805215412 @default.
- W4280521541 hasOpenAccess W4280521541 @default.
- W4280521541 hasPrimaryLocation W42805215411 @default.
- W4280521541 hasRelatedWork W2155654588 @default.
- W4280521541 hasRelatedWork W2285109017 @default.
- W4280521541 hasRelatedWork W2751400660 @default.
- W4280521541 hasRelatedWork W2785808209 @default.
- W4280521541 hasRelatedWork W2802256694 @default.
- W4280521541 hasRelatedWork W2969038597 @default.
- W4280521541 hasRelatedWork W3016783954 @default.
- W4280521541 hasRelatedWork W3021504039 @default.
- W4280521541 hasRelatedWork W3215044659 @default.
- W4280521541 hasRelatedWork W4292999071 @default.
- W4280521541 hasVolume "169" @default.
- W4280521541 isParatext "false" @default.
- W4280521541 isRetracted "false" @default.
- W4280521541 workType "article" @default.